Vera Therapeutics (VERA)
(Delayed Data from NSDQ)
$36.75 USD
+0.13 (0.35%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $36.76 +0.01 (0.03%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
VERA 36.75 +0.13(0.35%)
Will VERA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VERA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VERA
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
Wall Street Analysts Believe Vera Therapeutics, Inc. (VERA) Could Rally 86.76%: Here's is How to Trade
VERA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)
Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)
Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a Turnaround
Other News for VERA
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Appoints Christy Oliger to Board
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)